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Abstract
The effect of combining SU5416 with fractionated
radiotherapy or with low molecular weight (LMW)
heparin (dalteparin) was studied in U87 human glio-
blastoma xenografts in nude mice. SU5416 is antiangio-
genic by a specific inhibition of the vascular endothelial
growth factor receptor 2 (VEGFR-2), and heparins are
assumed to bind VEGF. Both SU5416 (100 mg/kg every
second day in 5 days) and 3 Gy5 produced moderate,
yet significant, growth inhibition. Tumors treated with
concomitant irradiation and short - term SU5416 main-
tained a lower growth rate during regrowth than the
other treatment groups (P=.007). Dalteparin (1000 IE/kg
subcutaneously once a day) had no growth- inhibitory
effect on its own, but when this LMW heparin was added
to the SU5416 schedule, a significantly enhanced
growth inhibition was obtained. VEGF protein content
in tumors was not significantly altered by SU5416, but a
significant decrease in VEGF levels was found in tumors
treated with concomitant dalteparin and SU5416 com-
pared with controls (P=.03). We conclude that: 1) an
additive growth- inhibitory effect is obtained by combin-
ing SU5416 and fractionated radiotherapy; and 2) LMW
heparin (dalteparin ), in combination with SU5416,
decreases the level of VEGF in tumors and increases
the growth- inhibitory effect of SU5416.
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Introduction
SU5416 is a small molecule inhibitor of tyrosine kinase
receptors, including the vascular endothelial growth factor
receptors (VEGFR-2) and the stem cell factor receptor
c-kit [1,2]. The compound can slow tumor growth in a
number of experimental tumors [3], and reduces vascular
density in glioblastomas [4].
Meta-analyses comparing cancer patients treated with
heparin or low molecular weight (LMW) heparin for venous
thromboembolism have shown that LMW heparin improves
the cancer outcome [5,6]. Heparins can affect tumors in
several ways, by interactions with growth factors, enzymes,
and structural proteins in the extracellular matrix, as well as
by direct interaction with cells [7]. Antiangiogenic effects of
LMW heparins have been shown in different studies [7–9].
The antiangiogenic mechanisms of LMW heparins may be
complex, including the different processes mentioned above
and the binding of angiogenic growth factors like VEGF and
bFGF to the LMW heparin [8].
In the present study, we combined SU5416 with ionizing
radiation ( IR) or with dalteparin, a LMW heparin, and
demonstrate that these combinations increase the growth-
inhibitory effect of SU5416 on glioblastoma growth.
Materials and Methods
U87 Cells In Vitro
The human glioblastoma cell line U87 MG was grown at
378C in a humidified atmosphere of 5% CO2 in 175-cm
2
(650 ml) CELLSTAR culture flasks. The medium used was
Eagle’s MEM containing 10% FCS and no antibiotics. Cells
were harvested in an exponential growth phase with a cell
scraper. Controls and irradiated cells were harvested and
kept on ice for 1 hour at the time of irradiation and
subsequently the cells were added to new culture flasks with
fresh medium. The cell medium was collected for analysis at
8, 24, and 48 hours after irradiation. Four independent
experiments were performed.
Tumor Xenografts
Male 7-week-old athymic nude mice (NMRI-nu/nu )
obtained from M&B (Ry, Denmark) were used. The mice
were kept in laminar airflow benches. They received sterile
food pellets and water ad libitum. Institutional guidelines for
animal welfare and experimental conduct were followed.
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Xenografts were established by subcutaneous injection of
tumor cells and maintained by serial transplantation. Prior
to transplantation, the mice were anesthesized by a sub-
cutaneous injection of ketamine (10 mg/kg) and xylazine (1
mg/kg) in 0.9% NaCl solution. Through a 1-cm incision in
the dorsal skin, 1-mm3 tumor blocks were subcutaneously
implanted into the flank. Tumors were measured daily during
tumor growth, by two orthogonal diameters d1 and d2. Tumor
volume was calculated according to the equation:
V ¼ p=6ðd1d2Þ3=2k
where k is an empirical constant equal to 0.67.
Thetumorvolumedoubling timeTDwascalculated foreach
individual tumor in the exponential growth phase after the
discontinuation of therapywith IRand/orSU5416. Thebest fit
exponential growth curve, V=aexp(bt ), was computed using
a SigmaPlot software program (SPSS, Holte, Denmark). The
tumor volume doubling time for each tumor TD is ln2/b.
Irradiation of Xenograft Tumors and Cell Cultures
A single dose of 10 or 15 Gy of IR, given as five daily
fractions of 3 Gy, was applied using a Stabilipan (Siemens,
Ballerup, DK) therapeutic unit that yields 4.58 Gy/min at 300
kV. Mice were anesthesized before each irradiation, as
described above.
Drugs
SU5416 was delivered subcutaneously in a centyl -
methyl -cellulose (CMC) suspension 100 mg/kg every
second day from the day tumors reached a volume threshold
of 120 mm3.
When combined with IR, the drug was given for a total
of three times (days 1 to 5 of radiation therapy). The drug
was delivered 1 to 2 hours before the IR. In another
experiment, SU5416 was given every second day until
tumors reached a volume of 600 mm3. In that experiment,
the drug was used as monotherapy or in combination with
dalteparin.
Dalteparin (Fragmin; Pharmacia, DK) was diluted in
isotonic saline and delivered subcutaneously 1 IU/g once a
day from the day tumors reached a volume of 120 mm3.
Dalteparin was used as monotherapy or in combination with
SU5416. Controls received no treatment.
Statistics
Student’s t - test was used to compare different treatment
groups.
VEGF ELISA Measurements
In the cell culture experiments, the cell number was
counted at the time of harvesting. The medium was briefly
spun, a proteinase inhibitor cocktail (Complete; Roche,
Mannheim, Germany) was added, and medium was frozen
in liquid nitrogen.
Tumor blocks were obtained at a tumor volume of
600 mm3 and homogenized with five short bursts on a
Vibra Cell 50 (Sonics & Materials, Danbury, CT). The
protein concentration was determined with a BCA Protein
Assay (Pierce, Rockford, IL). The VEGF protein content in
Figure 1. SU5416 treatment in combination with irradiation. Effects on tumor growth. Mean values of tumor volume in different treatment groups. Bars: interquartile
range. Treatment was initiated when tumors reached a volume of 120 mm3 and continued for 5 days. The tumor volume doubling time TD for each tumor was
determined in the exponential growth phase after discontinuation of therapy. The mean TD values in tumors treated with both SU5416 and IR were significantly
higher than in tumors treated with IR (P= .007, t - test ). The time for tumors to reach 800 mm3 was significantly longer in tumors treated with SU5416 than in controls
(P= .04, t - test ) and also longer in tumors treated with IR+SU5416 compared with IR alone (P= .03, t - test ).
,
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tumors and medium was determined using VEGF Quanti-
kine immunoassay kits (R&D Systems, Abingdon, UK).
Immunohistochemistry
Tissue slices from tumors were frozen in cooled iso-
penthane. Frozen sections were fixed in acetone and CD31
immunostaining was performed as follows. Sections were
washed in PBS and TBS and incubated with 10% rabbit
serum for 30 minutes. They were then incubated with a
mixture of two monoclonal rat antimouse CD31 antibodies at
a dilution of 20 g/ml overnight at 48C. The antibodies used
were clone 390 (Serotec, Oxford, UK) and MEC 13.3
(Pharmingen, San Diego, CA). Rat IgG2a (Serotec) was
used as a negative control. Sections were incubated with
biotin-conjugated rabbit antirat immunoglobulin (DAKO,
Glostrup, DK) at a dilution of 1:600 (2.3 g/ml) for 30
minutes, washed, and incubated with alkaline phosphatase–
conjugated streptavidin (DAKO) at a dilution of 1:200 (1.5
g/ml) for 30 minutes. As substrate for the alkaline
phosphatase reaction, we used freshly prepared Fast Red
Substrate System (DAKO), followed by a 10-minutes wash
in tap water. Finally, the sections were counterstained with
hematoxylin and mounted with aqueous mounting media.
Vessel Density
Vessel density was recorded as the number of point counts
of CD31-positive vessels per field, at 200 magnification,
viewed through an ocular Chalkley Point Array (Graticules,
Tonbridge, UK). Ten fields per section, randomly selected
from non-necrotic areas of tumors, were examined with
a Leica DMRB microscope (Herlev, DK). The examination
was blinded.
Interstitial Fluid Pressure ( IFP)
Tumor IFP measurements were performed by the wick-
in-needle technique, as described previously elsewhere
Figure 2. SU5416 treatment in combination with dalteparin. Effects on individual U87 tumor growth. Treatment was initiated when tumors reached a volume of
120 mm3, and continued until excision of tumors. Doses: 100 mg / kg SU5416 subcutaneously every second day; 1 IU /g dalteparin subcutaneously per day.
Table 1. Growth Characteristics of U87 Tumors After SU5416 and Dalteparin.
N T(early) T(late) T(growth)
Mean SD t - test Versus
Controls
Mean SD t - test Versus
Controls
Mean SD t - test Versus
Controls
Controls 15 3.5 1.6 2.6 0.7 6.1 1.7
SU5416 13 5.2 4.5 P= .20 3.8 2.2 P= .06 8.9 5.7 P= .11
Dalteparin 15 3.1 1.1 P= .43 2.1 0.6 P= .08 5.3 1.3 P= .13
SU5416+dalteparin 15 4.7 2.1 P= .09 8.3 10.9 P= .05 13.2 11.8 P= .04
For each individual tumor, the time of first measurement of a volume of 200, 400, and 600 mm3 was recorded.
T (early): The number of days from a volume of 200 mm
3 to a volume of 400 mm3.
T (late): The number of days from a volume of 400 mm
3 to a volume of 600 mm3.
T (growth): The number of days from a volume of 200 mm
3 to a volume of 600 mm3.
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[10]. The IFP was recorded at tumor volumes of 600 mm3,
just before the mice were sacrificed and the tumors excised
for histological examination and VEGF measurements.
Results
Effects of Treatment on Tumor Growth
SU5416 had a moderate, but significant, growth-
inhibitory effect as short - term monotherapy (Figure 1). In
contrast, fractionated irradiation 3 Gy5 had a longer-
lasting effect on tumor growth. There was an additive effect
of combining irradiation with SU5416 on tumor growth
(Figure 1). In parallel, we tested the effect of combining
SU5416 with dalteparin. Here the tumors were excised at a
tumor size of 600 mm3 and processed for VEGF measure-
ments. Dalteparin, in combination with SU5416, resulted in a
significant inhibition of tumor growth, compared with controls
(Figure 2, Table 1). There was no growth- retarding effect of
dalteparin alone, rather a tendency towards a faster and a
more uniform tumor growth appeared, compared with
untreated controls (Figure 2, Table 1).
VEGF Expression After Therapy
The level of secreted VEGF protein in the growth medium
of U87 cells in vitro was higher than in controls 48 hours after
10 Gy irradiation (Figure 3).
In contrast, the VEGF level was significantly reduced in
U87 tumors treated with SU5416 in combination with
dalteparin, compared with control tumor levels (Table 2).
When 100 mg/kg SU5416 was administered in a CMC
suspension subcutaneously every second day as mono-
therapy, the reduction in VEGF was not significant.
Dalteparin monotherapy did not significantly change VEGF
levels either.
Vessel Density After Treatment
Chalkley counting was performed in four to five U87
tumors from each of four groups treated with SU5416,
dalteparin or dalteparin+SU5416, or no treatment. All
tumors were evaluated at a tumor size of 600 mm3. No
difference in vessel density was found between these
treatment groups (Table 3).
IFP
Because VEGF is known to be a permeability factor,
differences in VEGF levels in tumors might lead to differ-
ences in vessel permeability, resulting in differences in the
IFP in tumors. Wemeasured the IFP in untreated tumors and
in tumors treated with SU5416, dalteparin, or both. IFP was
measured at a tumor size of 600 mm3, immediately before
excision of tumors and preparation of tumor tissues for
VEGF measurements. There was no difference in tumor IFP
between these different treatment groups (Figure 4).
Figure 3. Relative VEGF levels in medium from U87 cell cultures after 10 Gy
of irradiation. The VEGF level following 0 Gy (sham- irradiated ) was 1.0. At
48 hours, the VEGF levels were increased in four of four experiments to a
value of 1.6 to 2.6 (P= .025, t - test ). No significant upregulation was seen at
8 and 24 hours. Bars: standard deviation. Four independent experiments
were performed.
Table 2. VEGF Protein Levels in U87 Tumors After SU5416 and Dalteparin.





SD t - test
Compared
with Controls
Controls 15 236 88
SU5416 13 176 108 NS
Dalteparin 15 205 103 NS
SU5416+dalteparin 15 159 94 P= .03
Dalteparin, in combination with SU5416, significantly reduced the VEGF
content in tumors compared with controls. The reduction after SU5416 or
dalteparin as monotherapy was not statistically significant. There was no
statistical difference in VEGF levels between the different treatment groups.
The VEGF levels were measured at a tumor volume of 600 mm3.
NS=no significant difference.
Table 3. Vessel Density in U87 Tumors After SU5416 and Dalteparin.










Controls 50 5.1 1.6
SU5416 40 5.1 1.9 NS
Dalteparin 50 4.8 1.7 NS
SU5416+dalteparin 40 5.5 2.1 NS
NS=no significant difference.
Figure 4. IFP after SU5416 and dalteparin treatment in U87 tumors. No
significant difference between treatment groups was found. Each box shows
the median, quartiles, and extreme values within a category.
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Discussion
We report that combinations of the VEGFR-2 inhibitor
SU5416 with the LMW heparin dalteparin or IR can additively
increase the effect on glioblastoma growth.
The role of endothelial cell kill in the biological effect of
ionizing irradiation effects was recently discussed by Folk-
man and Camphausen [11]. It is known that the apoptosis of
endothelial cells after irradiation can be avoided or
decreased by the addition of the angiogenic growth factors
bFGF [12] or VEGF [13], and that the killing of endothelial
cells and the regression of vessels are increased by blocking
the VEGF response by VEGF antibodies, soluble VEGFR, or
SU5416 [13,14].
Here we found an additive effect on the growth inhibition
of SU5416 and fractionated radiotherapy with 3 Gy on five
concomitant days in U87 glioblastoma tumors. In another
glioblastoma line GL261, a similar additive effect of
combining IR and SU5416 has been shown [14]. Doses
of 30 and 70 Gy of IR, in combination with a monoclonal
antibody against VEGFR-2, also showed an additive effect
on U87 xenograft growth [15]. So the present findings add to
the accumulating evidence that concomitant blockage of the
VEGFR-2 signaling increases the effect of IR on glioblas-
toma growth.
Antiangiogenic treatment strategies aiming at other
targets than survival signaling through the VEGFR-2 have
shown a comparable potentiation of the effect of IR on tumor
growth in several studies (e.g., [16,17] ). In accordance,
adding the growth factors VEGF or bFGF before irradiation
protects against radiation- induced apoptosis in normal gut
epithelial cells [18].
Secreted VEGF was upregulated in U87 cells in vitro
after 10 Gy. This induction of VEGF secretion by irradiation
is in line with previous findings both in vitro and in tumor
extracts [13].
The observation that dalteparin had no growth- inhibitory
effect alone, whereas combination treatment with SU5416
increased the growth inhibition of SU5416, along with a
reduction of the VEGF content in tumors, holds significant
clinical promise. The antiangiogenic mechanism of LMW
heparin is not clear, but it is known that LMW heparins bind
VEGF, and it is likely that the combination of a competitive
binding of VEGF by dalteparin increases the effectiveness of
a concomitant blockage of the VEGF receptor. Another
explanation could be that dalteparin treatment rendered a
more uniform dose distribution of SU5416 in solid tumors by
a reduced microthrombus formation and a correspondingly
improved perfusion rate. To the extent that thrombosis of
tumor vessels plays a role in the normal variation in growth of
untreated tumors, the antithrombotic effect of dalteparin
might similarly explain the uniformly exponential growth in
the dalteparin- treated tumors compared with controls.
VEGF is a permeability factor, and VEGF overexpression
leads to a formation of leaky vessels [19]. VEGF over-
expression leads to a formation of interendothelial gaps or
transendothelial pores accounting for the hyperpermeability
to plasma proteins and other circulating agents [20].
Because VEGF is overexpressed in many tumors, including
U87 glioblastoma, we hypothesized that a reduction in VEGF
levels in tumors might also reduce the IFP.
The IFP showed a great intertumor variation, similar to the
experiences with other tumors [21]. IFP levels in U87 tumors
were not changed by treatment with dalteparin and SU5416,
despite a decrease in VEGF protein levels in the same
tumors compared with controls. One explanation for this may
be that some tumor vessels have defective cellular lining
composed of disorganized, loosely connected endothelial
cells with defects where tumor cells are directly in contact
with the lumen [22,23]. The permeability of such vessels
could be largely refractory to changes in VEGF, if they have
large openings between endothelial cells. In that case, the
fine- tuning of permeability through regression of trans-
endothelial or interendothelial pores due to VEGF would
make no differences to the overall permeability.
Vessel density, estimated by Chalkley counting, was
unchanged in U87 tumors treated with SU5416 and
dalteparin compared to controls. The vessel density was
measured at the same tumor size (600 mm3) in controls and
treated tumors ( i.e., the treated tumors were growing at the
time of sampling). In a study by Vajkoczy et al. [4], SU5416
was found to reduce the fractional area of microvasculature
in C6 glioma. There the SU5416 treatment was initiated from
day 0 after implantation of tumor cells. In the present study,
treatment was initiated when tumors were established and
growing. SU5416 has been shown to delay the angiogenic
switch [24], and in breast cancer, VEGF is essential for the
initial, but not continued, growth of tumors [25]. The
difference in vessel density response between the C6 study
and the present work may be due to a selection pressure in
the early critical phase of tumor establishment towards tumor
cell subclones with lower oxygen and nutrient requirements.
In summary, we find that SU5416 has an additive effect on
tumor growth in combination with fractionated radiotherapy,
and that the LMW heparin, dalteparin, in combination with
SU5416, increases the growth- inhibitory effect of SU5416
and decreases the level of VEGF in U87 glioblastomas. This
may be of particular therapeutic relevance, and a clinical
evaluation of combinations of tyrosine kinase inhibitors with
IR and LMW heparin is warranted.
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